RXRX
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the...
Read moreDetails
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this...
Read moreDetails
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding...
Read moreDetails